| Efficacy and Safety of Org 25969 Administered After Zemuron® (MK-8616-042) (NCT03519867) | Merck Sharp & Dohme LLC | 2004-08-01 |
| Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis (0000-041) (NCT00211601) | Merck Sharp & Dohme LLC | 2004-08-01 |
| A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED) (NCT00239655) | Merck Sharp & Dohme LLC | 2004-08-01 |
| 12-Week No-Rofecoxib Plus Aspirin Endoscopy Study (0782-003) (NCT00543465) | Merck Sharp & Dohme LLC | 2004-08-01 |
| MK0524A Phase IIb Study (0524A-011)(COMPLETED) (NCT00536237) | Merck Sharp & Dohme LLC | 2004-08-01 |
| Endpoint Validation Study (0524A-015) (NCT00533676) | Merck Sharp & Dohme LLC | 2004-08-01 |
| MK0916 in Patients With Type 2 Diabetes and Metabolic Syndrome (0916-005) (NCT00543595) | Merck Sharp & Dohme LLC | 2004-08-01 |
| An Investigational Drug Study in Obese (Considerably Overweight) Patients (0364-006) (NCT00109148) | Merck Sharp & Dohme LLC | 2004-07-01 |
| MK0686 in Postsurgery Dental Pain (0686-002) (NCT00533403) | Merck Sharp & Dohme LLC | 2004-07-01 |
| Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004) (NCT00105469) | Merck Sharp & Dohme LLC | 2004-07-01 |
| Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C (NCT00120835) | Merck Sharp & Dohme LLC | 2004-07-01 |
| Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003) (NCT00105534) | Merck Sharp & Dohme LLC | 2004-07-01 |
| Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED) (NCT00087451) | Merck Sharp & Dohme LLC | 2004-07-01 |
| A Study to Determine the Efficacy and Safety of 2 Doses of Org 34517 as Adjunctive Therapy in Subjects With Psychotic Major Depression (28130)(P05845) (NCT00212797) | Merck Sharp & Dohme LLC | 2004-07-01 |
| Comparison of Osteoporosis Disease Management Strategies (0000-039) (NCT00145080) | Merck Sharp & Dohme LLC | 2004-07-01 |
| Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED) (NCT00086515) | Merck Sharp & Dohme LLC | 2004-06-30 |
| A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019) (NCT00090220) | Merck Sharp & Dohme LLC | 2004-06-16 |
| A Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822) in Healthy Volunteers (NCT00863590) | Merck Sharp & Dohme LLC | 2004-06-01 |
| Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021) (NCT00087516) | Merck Sharp & Dohme LLC | 2004-06-01 |
| Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus (NCT00086502) | Merck Sharp & Dohme LLC | 2004-06-01 |
| Efficacy, Tolerability and Safety Study in Rheumatoid Arthritis (0812-008) (NCT00542022) | Merck Sharp & Dohme LLC | 2004-06-01 |
| Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED) (NCT00086125) | Merck Sharp & Dohme LLC | 2004-06-01 |
| Investigation of 9 Consecutive Remicade Infusions in Ankylosing Spondylitis in Austria (Study P04044)(COMPLETED) (NCT00725543) | Merck Sharp & Dohme LLC | 2004-06-01 |
| Bioequivalence of Two Formulations of Ondansetron in Healthy Adults (0869-106) (NCT00972595) | Merck Sharp & Dohme LLC | 2004-06-01 |
| MK0782 + Low-Dose Aspirin 7-Day Erosion Endoscopy Study (0782-001) (NCT00543868) | Merck Sharp & Dohme LLC | 2004-06-01 |
| An Investigational Drug Study In Patients With COPD (Chronic Obstructive Pulmonary Disease) (MK-0873-005) (NCT00132730) | Merck Sharp & Dohme LLC | 2004-06-01 |
| Study of Diquafosol Tetrasodium Ophthalmic Solution in Subjects With Dry Eye Disease (NCT00403975) | Merck Sharp & Dohme LLC | 2004-06-01 |
| Study of Denufosol (INS37217) in Subjects With Rhegmatogenous Retinal Detachment (NCT00083967) | Merck Sharp & Dohme LLC | 2004-06-01 |
| MK-0431 Early Phase II Double-blind Study - Type 2 Diabetes Mellitus (0431-043) (NCT00371007) | Merck Sharp & Dohme LLC | 2004-06-01 |
| A Study of Rofecoxib in the Treatment of Post-Operative Pain After Total Knee Joint Replacement (0966-259) (NCT00140920) | Merck Sharp & Dohme LLC | 2004-05-25 |
| 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091) (NCT00090246) | Merck Sharp & Dohme LLC | 2004-05-13 |
| Study of Safety, Tolerability and Efficacy of MK0493 in Obese Patients (0493-008)(COMPLETED) (NCT00482638) | Merck Sharp & Dohme LLC | 2004-05-12 |
| Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia (0991-042) (NCT00292071) | Merck Sharp & Dohme LLC | 2004-05-01 |
| MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022) (COMPLETED) (NCT00857311) | Merck Sharp & Dohme LLC | 2004-05-01 |
| Caspofungin for the Treatment of Non-blood Candida Infections (0991-045) (NCT00083343) | Merck Sharp & Dohme LLC | 2004-05-01 |
| Documented Candida or Aspergillus Infections in Pediatric Patients (0991-043) (NCT00082524) | Merck Sharp & Dohme LLC | 2004-04-01 |
| MK0991 Versus Amphotericin B for Empirical Therapy in Febrile, Neutropenic Pediatric Patients (0991-044) (NCT00082537) | Merck Sharp & Dohme LLC | 2004-04-01 |
| A Study of MK0431 in Patients WIth Hepatic Insufficiency (0431-017)(COMPLETED) (NCT00696826) | Merck Sharp & Dohme LLC | 2004-04-01 |
| Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097) (NCT00080444) | Merck Sharp & Dohme LLC | 2004-04-01 |
| Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247) (NCT00076856) | Merck Sharp & Dohme LLC | 2004-03-31 |
| Dose-Finding Trial With Sugammadex Administered at 3 and 15 Minutes After 1.0 and 1.2 mg/kg Rocuronium Bromide in Participants of ASA Class 1-3 (P05944; MK-8616-024) (NCT00535743) | Merck Sharp & Dohme LLC | 2004-03-04 |
| Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471) (NCT00081770) | Merck Sharp & Dohme LLC | 2004-03-01 |
| Real Life Dosing of Remicade for Rheumatoid Arthritis in Austria Monitored Over 9 Infusions (Study P03756)(COMPLETED) (NCT00725621) | Merck Sharp & Dohme LLC | 2004-03-01 |
| Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED) (NCT00533481) | Merck Sharp & Dohme LLC | 2004-02-01 |
| Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED) (NCT00090207) | Merck Sharp & Dohme LLC | 2004-01-13 |
| A Study of Rofecoxib Versus Naproxen in the Treatment of Chinese Patient With Rheumatoid Arthritis (0966-231) (NCT00157872) | Merck Sharp & Dohme LLC | 2004-01-07 |
| A Study of MK0217A and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227) (NCT00092079) | Merck Sharp & Dohme LLC | 2004-01-01 |
| A Study to Evaluate Ertapenem Versus It's Comparator in the Treatment of Complicated Intra-abdominal Infections in Adults (0826-050)(COMPLETED) (NCT00157898) | Merck Sharp & Dohme LLC | 2004-01-01 |
| Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137) (NCT00686517) | Merck Sharp & Dohme LLC | 2003-12-01 |
| A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004) (NCT00109109) | Merck Sharp & Dohme LLC | 2003-12-01 |
| Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480) (NCT00081510) | Merck Sharp & Dohme LLC | 2003-12-01 |
| Use of Sugammadex Administered at 5 Minutes After Administration of 1.2 mg/kg Esmeron® (19.4.205)(P05942) (NCT00379613) | Merck Sharp & Dohme LLC | 2003-11-07 |
| A Bioequivalence Study of 3 Formulations of Ondansetron in Healthy Adults (0869-095)(COMPLETED) (NCT00971633) | Merck Sharp & Dohme LLC | 2003-11-01 |
| Osteoporosis Disease Management Demonstration Project (0000-040) (NCT00145067) | Merck Sharp & Dohme LLC | 2003-11-01 |
| A 1-Year Study of an Investigational Drug in Obese Patients (0557-012)(COMPLETED) (NCT00092872) | Merck Sharp & Dohme LLC | 2003-11-01 |
| Efficacy of Infliximab in the Treatment of Patients Affected by Corticodependent Crohn's Disease (P02732) (NCT00796250) | Merck Sharp & Dohme LLC | 2003-11-01 |
| A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) (NCT00092547) | Merck Sharp & Dohme LLC | 2003-10-08 |
| A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625) (NCT00780039) | Merck Sharp & Dohme LLC | 2003-10-01 |
| Evaluation of the Safety and Tolerability of a Higher Potency Dose of an Investigational Vaccine Among Adults 50 Years of Age and Older (V211-009) (NCT00092417) | Merck Sharp & Dohme LLC | 2003-10-01 |
| Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED) (NCT00074529) | Merck Sharp & Dohme LLC | 2003-10-01 |
| 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED) (NCT00090155) | Merck Sharp & Dohme LLC | 2003-09-26 |
| A Study of Two Approved Drugs in the Treatment of Post-Bunionectomy Surgery Pain (0966-234)(COMPLETED) (NCT00092378) | Merck Sharp & Dohme LLC | 2003-09-01 |
| Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530) (NCT00073450) | Merck Sharp & Dohme LLC | 2003-09-01 |
| Efficacy & Safety of Loratadine-Betamethasone Oral Solution for Treatment of Severe Perennial Allergic Rhinitis in Children (Study P03428) (NCT00963573) | Merck Sharp & Dohme LLC | 2003-09-01 |
| A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014) (NCT00481663) | Merck Sharp & Dohme LLC | 2003-08-19 |
| A 2-Year Study of an Investigational Drug in Obese Patients (0557-011) (NCT00092859) | Merck Sharp & Dohme LLC | 2003-08-01 |
| MK0767 Added to Insulin Therapy in Patients With Type 2 Diabetes (0767-030) (NCT00543816) | Merck Sharp & Dohme LLC | 2003-08-01 |
| Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548) (NCT00302081) | Merck Sharp & Dohme LLC | 2003-08-01 |
| Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035) (NCT00705614) | Merck Sharp & Dohme LLC | 2003-07-01 |
| Remicade Safety Line (Ankylosing Spondylitis)(Study P03275)(COMPLETED) (NCT00818168) | Merck Sharp & Dohme LLC | 2003-07-01 |
| Dyslipidemia in Type 2 Diabetes (0767-034) (NCT00547274) | Merck Sharp & Dohme LLC | 2003-07-01 |
| MK0524 Seasonal Allergic Rhinitis Study (0524-005)(COMPLETED) (NCT00533208) | Merck Sharp & Dohme LLC | 2003-07-01 |
| Efficacy of Remicade in the Treatment of Active Rheumatoid Arthritis Despite Methotrexate (Study P03027) (NCT00794898) | Merck Sharp & Dohme LLC | 2003-07-01 |
| Study of Efficacy, Pharmacokinetics, and Safety of Bolus Maintenance Doses of Org 9426 (Study P05976)(COMPLETED) (NCT00984633) | Merck Sharp & Dohme LLC | 2003-06-01 |
| A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018) (NCT00849732) | Merck Sharp & Dohme LLC | 2003-06-01 |
| MK0767 and Metformin Combination Study (0767-028) (NCT00543738) | Merck Sharp & Dohme LLC | 2003-06-01 |
| SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745) (NCT00783393) | Merck Sharp & Dohme LLC | 2003-05-27 |
| A Study of MK0431 in Patients With Type 2 Diabetes (0431-010) (NCT00482079) | Merck Sharp & Dohme LLC | 2003-05-13 |
| Osteoporosis Disease Management Demonstration Project (0000-037) (NCT00139425) | Merck Sharp & Dohme LLC | 2003-05-01 |
| Study MK0767 and Metformin in Type 2 Diabetic Patients (0767-020) (NCT00543361) | Merck Sharp & Dohme LLC | 2003-05-01 |
| Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED) (NCT00060645) | Merck Sharp & Dohme LLC | 2003-05-01 |
| MK0767 and Sulfonylurea Combination Study (0767-027) (NCT00543491) | Merck Sharp & Dohme LLC | 2003-05-01 |
| Consistency Lots Vaccine Study (V260-009) (NCT00092456) | Merck Sharp & Dohme LLC | 2003-05-01 |
| Study of Efficacy, Pharmacokinetics and Safety of Continuous Intravenous Infusion of Org 9426 (Study P05977) (NCT00988520) | Merck Sharp & Dohme LLC | 2003-05-01 |
| Instrument Utility for Suspected Asthma (0000-042)(COMPLETED) (NCT00211575) | Merck Sharp & Dohme LLC | 2003-05-01 |
| A Study of Safety, Tolerability and Immunogenicity of a 1-Dose Regimen of MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC_HIV Vaccine (V520-019) (NCT00894114) | Merck Sharp & Dohme LLC | 2003-05-01 |
| A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-219) (NCT00092352) | Merck Sharp & Dohme LLC | 2003-04-29 |
| A Study to Evaluate Rofecoxib Versus Placebo and Diclofenac in Patients With Acute Painful Rotator Cuff Syndrome (NCT00140933) | Merck Sharp & Dohme LLC | 2003-04-01 |
| A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016) (NCT00849680) | Merck Sharp & Dohme LLC | 2003-04-01 |
| Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED) (NCT00060632) | Merck Sharp & Dohme LLC | 2003-04-01 |
| Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease (NCT00056147) | Merck Sharp & Dohme LLC | 2003-04-01 |
| A Pharmacokinetic Evaluation Study in Healthy Volunteers (NCT00210093) | Merck Sharp & Dohme LLC | 2003-04-01 |
| A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-220)(COMPLETED) (NCT00092365) | Merck Sharp & Dohme LLC | 2003-04-01 |
| A Study to Evaluate Safety and Efficacy of Caelyx in Combination With Cyclophosphamide in the Treatment of Metastatic Breast Cancer (P02948) (NCT00779129) | Merck Sharp & Dohme LLC | 2003-03-01 |
| Dose Escalation Study to Evaluate the Safety and Antiviral Activity of Val-mCyd in Adults With Chronic Hepatitis C (NCT00227435) | Merck Sharp & Dohme LLC | 2003-02-01 |
| Study A - MK0767 Monotherapy Study (NCT00543517) | Merck Sharp & Dohme LLC | 2003-02-01 |
| Fenofibrate Bioequivalence Study (0767-031) (NCT00928694) | Merck Sharp & Dohme LLC | 2003-02-01 |
| Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED) (NCT00811967) | Merck Sharp & Dohme LLC | 2003-02-01 |
| Comparative Study of Rocuronium With Vecuronium (Study 71101)(COMPLETED) (NCT00970762) | Merck Sharp & Dohme LLC | 2003-02-01 |
| Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201) (NCT00060476) | Merck Sharp & Dohme LLC | 2003-01-08 |